Why the nasal vaccine developed by Bharat Biotech might be a useful choice ?
For individuals over 18, the first intranasal COVID-19 vaccination in the nation is now accessible as a booster dose. This vaccine is administered intravenously rather than intramuscularly. The nasal vaccination, created by Bharat Biotech, is now available as a heterologous booster dosage for those who have already taken Covishield and Covaxin.
The needle-free vaccine has been introduced on the Co-WIN platform and will be offered at private clinics. The Indian Drugs Controller General gave his approval to the nasal vaccination BBV154, also known as iNCOVACC, in November.
NO NEED FOR NEEDLES
All COVID-19 vaccinations now available do not require the use of needles or syringes because the vaccine is administered by nasal spray. It will also lessen the need for medical workers with shot-giving training.
WHY NASAL SPRAY CAN BE EFFECTIVE ?
The vaccination causes the mucosal barrier to mount an immune response while it is administered nasally. According to the manufacturer, “BBV154 may develop local antibodies in the upper respiratory tract as a result of being an intranasal vaccination, which may give the potential to minimise infection and transmission.” We do not have any statistics to say that for sure, according to Dr. Anurag Agarwal, dean of biosciences and health research at the Trivedi School of Biosciences of Ashoka University. We can say that the nasal vaccination is more likely to be successful at preventing transmission than the present generation of vaccines since it provides local protection (in the nose where the virus initially enters).However, there’s still opportunity for development. This is just one of many vaccines in the upcoming generation.
WHY IS THE NASAL VACCINE PRACTICAL FOR THE FUTURE?
“A nasal vaccination or something similar works. This is due to the fact that it offers local immunity and is convenient to administer without the use of syringes or skilled personnel. Second, it will be inexpensive and useful. This would result in reduced costs as well as simpler distribution, a lack of demand for extremely chilly cold chains, and other benefits. To cover a wider range of the Sars-CoV-2 virus, it may be created as a multivalent drug, he adds.
TRIALS FOR BOOSTER
Bharat Biotech created the vaccine using technology that was licenced from Washington University in St. Louis. When compared to its own Covaxin, the business concluded that the vaccine was “safe, well-tolerated, and immunogenic” in a phase III trial involving roughly 3,100 participants at 14 sites in India. In order to determine if the vaccine can be administered as a booster shot to people who have already received Covaxin or Covishield as their initial vaccination, the business also performed a trial with 875 participants.